BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH

Similar documents
INSULIN 101: When, How and What

PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification

PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES

Tips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital

What s New in Type 1 and Type 2 Diabetes? Updates from 2013 CDA CPGs and Advancements in Insulin Therapy

CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia

These results are supplied for informational purposes only.

New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011

Injecting Insulin into Out Patient Practice

Starting and Helping People with Type 2 Diabetes on Insulin

ClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:

Update on Insulin-based Agents for T2D. Harry Jiménez MD, FACE

Pramlintide & Weight. Diane M Karl MD. The Endocrine Clinic & Oregon Health & Science University Portland, Oregon

Mixed Insulins Pick Me

Faculty. Timothy S. Reid, MD (Co-Chair, Presenter) Medical Director Mercy Diabetes Center Janesville, WI

Sample Exam Questions

LET S TALK INSULIN THE BASICS

Very Practical Tips for Managing Type 2 Diabetes

Self-Monitoring Blood Glucose (SMBG) Frequency & Pattern Tool

Complete this CE activity online at ProCE.com/InsulinPart2

Insulin Initiation, titration & Insulin switch in the Primary Care-KISS

Comprehensive Diabetes Treatment

Individualizing Care for Patients with Type 2 Diabetes

Type 2 Diabetes Mellitus Insulin Therapy 2012

Timely!Insulinization In!Type!2! Diabetes,!When!and!How

Basal Insulin Drug Class Prior Authorization Protocol

Insulin Basics. Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology

Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM

NMQF. Washington DC 2014

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)

Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials

APPENDIX American Diabetes Association. Published online at

Navigating the New Options for the Management of Type 2 Diabetes

Poll Question 2. Special Boot Camp Workshop Beverly Dyck Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services.

INSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)

Early treatment for patients with Type 2 Diabetes

Ways to talk about Diabetes Meds Tom Ransom Div. Endocrinology, Capital Health April 5, 2018

GLP-1RA and insulin: friends or foes?

Insulin 10/11/17. Disclosures. Objectives. Speaker and Consultant for Jansen and Healthscripts Speaker and Consultant for Boehringer Ingelheim (BI)

INSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد

Initiation and Adjustment of Insulin Regimens for Type 2 Diabetes

Reviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate

This article is a CME/CE certified activity. To earn credit for this activity visit:

Sponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1

This case study is supported by an educational grant from Abbott.

Quando l insulina basale non basta più: differenti e nuove strategie terapeutiche

Subjects are requested to perform self-monitoring of blood glucose (SMBG) 4 times per

DIABETES DEBATE - IS NEW BETTER?

Long-acting insulins for the management of type 2 diabetes

Insulin Prior Authorization with optional Quantity Limit Program Summary

This certificate-level program is non-sponsored.

Presented by Dr. Bruce Perkins, MD MPH Dr. Michael Riddell, PhD

Diabetes Management in New Brunswick Nursing Homes

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection

nocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded

Quick Reference Guide

Basal Bolus Insulin Therapy Frequently Asked Questions

Sponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine)

Insulin Intensification: A Patient-Centered Approach

Glucose Control and Prevention of Cardiovascular Disease

Insulin 301: Case, after case, after case

Sponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1

In-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University

Update on Insulin-based Agents for T2D

Your Chart Review Data. Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine

Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol

Individualising Insulin Regimens: Premixed or basal plus/bolus?

INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE

Innovative, Unusual Therapies for DM-2: Insulin U-500, Bromocriptine, Colesevelam, and SGLT2 inhibitors. April 3 rd, 2014

Insulin Initiation and titration in the Primary Care-KISS Rotorua GP CME Meeting June 2011

Diabetes Care Publish Ahead of Print, published online June 1, 2009

Position Statement of ADA / EASD 2012

Important Stuff. Basal Bolus What Adjustments? Pt weighs 80kg

Against All Odds. Improving Insulin Use in T2DM Through Individualized Clinical Decision Making. June 16, 2014

Insulin Initiation and Intensification. Disclosure. Objectives

Module 5. Understanding Insulin Therapy

Incredible Incretins Abby Frye, PharmD, BCACP

Guide to Starting and Adjusting Insulin for Type 2 Diabetes*

Application of the Diabetes Algorithm to a Patient

Safe use of insulin regular concentrated (500 units/ml) in severe insulin resistance

STEP THERAPY CRITERIA

INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION

Questions may not always match the order of those online. Please be sure to read the questions when completing the online test.

Inpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 10, :30 a.m. 11:15 a.m.

Mr Rab Burtun. Dr David Kim. 8:30-10:30 WS #2: Diabetes Basic 11:00-13:00 WS #9: Diabetes Basic (Repeated)

Diabetes Head to Toe May 31, 2017

Original Article. Allen B. King, MD; Dawn Clark, ANP ABSTRACT

Evolving insulin therapy: Insulin replacement methods and the impact on cardiometabolic risk

Faculty. Concentrated Insulin: Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management. Disclosures. Learning Objectives

Optimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes

Insulin therapy in type 2 diabetes (workshop)

The New Age of Insulin: Exploring the Latest Trends in Insulin Therapy. The New Age of Insulin: Exploring the Latest Trends in Insulin Therapy

This program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.

Providing Stability to an Unstable Disease

5/16/2018. Insulin Workshop. Disclosures to Participants. Learning Objectives. This presentation will cover the following learning objectives:

5/16/2018. Insulin Update: New and Emerging Insulins. Disclosures to Participants. Learning Objectives

Target Audience. approach this patient case scenario, including identifying an

Transcription:

Insulin Initiation BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH

Disclosures In the past 12 months, I have received speakers honoraria from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Merck, NovoNordisk, Pfizer, Sanofi Aventis, and Servier. I have received travel funding from Pfizer, Sanofi Aventis, Merck, and AstraZeneca I have no financial interest in any pharmaceutical company

Objectives To identify patients appropriate for insulin inititiation. To select an appropriate insulin for patients beginning insulin therapy. To become familiar with a practical way of intitiating and titrating insulin.

Case 1 Mr. Jones, 58 year old male, 100 kg, BMI 35, T2DM 8 yrs, A1C = 8.2% On metformin 1gm BID, gliclazide MR 120mg OD, sitagliptin 100mg OD Breakfast Lunch Dinner Bedtime 10.5 8.5 8.1 8.0 Is this patient well controlled? Does this patient require insulin? If yes How would you start insulin here? How do you titrate the insulin dose? What do you do with the oral agents?

Target A1C** (%) Fasting/Pre-meal (mmol/l) 2-hour Post-meal (mmol/l) Target most patients apple 7.0 4.0 7.0 5.0 10.0 Normal Range Consider for patients in whom it can be achieved safely apple 6.0 4.0 6.0 5.0 8.0 Treatment goal and strategies must be tailored to the patient, with consideration given to individual risk factors ^Glycemic targets for children apple 12 years of age and pregnant women differ from these targets **An A1C of 7% corresponds to laboratory value of 0.070. Where possible, Canadian laboratories should standardize their A1C value to DCCT levels (0.04-0.06). A1C target of 7.0% refers to approximately 15% above the upper limit of normal CDA 2003 CPG, Can J Diabetes 27(Suppl 2):S19 2003

When to initiate insulin In people with type 2 diabetes, if individual treatment goals have not been reached with a regimen of nutrition therapy, physical activity and sulfonylurea, sulfonylurea plus metformin or other oral antihyperglycemic agents, insulin therapy should be initiated to improve glycemic control. Insulin may be used as initial therapy in type 2 diabetes, especially in cases of marked hyperglycemia (A1C 9.0%) CDA Clinical Practice Guidelines Expert Committee. Can J Diabetes 2008; 32(suppl 1):S1-S201.

When to initiate insulin (practically) Basically, if adjusting oral agents is unlikely to achieve target. For example, if on one oral and A1c is >8.5%, on 2 orals and A1c is >8.0%, or on three orals and above 7.0 (assuming target of 7.0 for the patient). After several years of diabetes, it is unlikely that someone suddenly will change lifestyle enough to significantly impact A1c escalate therapy (e.g. insulin), and later can back off if they really do change and sugars come way down.

Case With an A1C of 8.2% and all fasting readings above 7, this patient is not well-controlled. As they are already on 3 oral agents at maximum dose, Insulin is appropriate therapy for this person. So: What insulin? What dose? What about the orals?

Action Profiles of Bolus & Basal Insulins lispro/aspart/glulisine 4 6 hours BOLUS INSULINS regular 6-10 hours BASAL INSULINS Plasma Insulin levels NPH 12 20 hours detemir ~ 6-23 hours (dose dependant) glargine ~ 20-26 hours Hours Note: action curves are approximations for illustrative purposes. Actual patient response will vary. Mayfield, JA.. et al, Amer. Fam. Phys.; Aug. 2004, 70(3): 491 Plank, J. et.al. Diabetes Care, May 2005; 28(5): 1107-12

Basal selection NPH Pros: Cheapest, covered by Pharmacare, similar A1c results Cons: Inferior in terms of overall hypoglycemia, especially nocturnal hypoglycemia. Glargine Pros: Cheaper than detemir, truly 24 hours, minimal hypoglycemia Cons: More expensive than NPH, more weight gain than detemir Detemir Pros: Sometimes 24 hours, minimal hypoglycemia, least weight gain Cons: Most expensive, often not 24 hour?

Bottom line on basal If no drug coverage: Start with NPH, only switch if hypoglycemia is a problem. If drug coverage: Select basal of your choice. I would generally use an analogue.

Case Mr. Jones is on family pharmacare. You elect to start NPH What dose?

Case You give Mr. Jones a prescription for NPH 10 units subcutaneously at bedtime. You send him to the diabetes education centre for insulin teaching and instructions for titrating insulin by one unit every 1-2 days if his sugars remain above 7.0 in the morning, or until he is experiencing lows.